(Reuters Health)—Middle-aged women who get poor quality sleep have elevated levels of inflammatory markers, suggesting their risk for heart disease and other illnesses may be increased, U.S. researchers say. Based on sleep monitoring and blood tests of 295 women, most of whom were past menopause, researchers found those who had trouble falling asleep or who…
Data Show Outreach Is Working, But Does Rheumatology Have Enough Positions Available?
New data indicate that outreach is working: the interest of young medical professionals in rheumatology is growing. But as this interest grows, so will demand for rheumatology positions and funding for fellowships. The ACR has a plan to address these needs…
Nonopioid Medication May Be as Effective as Opioids for Chronic Pain
A recent study compared the efficacy of opioids with nonopioid pain treatments in patients with chronic back pain and hip or knee osteoarthritis. After 12 months, researchers found that treatment with opioids was not superior to treatment with nonopioid medication, with only minor differences in patients’ functional responses to the medications…
CVS Rolls Out New Tool to Combat Rising Drug Prices
(Reuters)—Drugstore chain CVS Health Corp on Wednesday launched a new tool that will allow pharmacies help customers tackle the soaring cost of drugs by comparing prices of medicines. U.S. healthcare companies, ranging from insurers to drug retailers, are stepping up efforts to combat rising drug prices that has been widely criticized by regulators and has…
ACR Named a Top Atlanta Workplace for 2nd Consecutive Year
In a designation based on employee opinion, the ACR has been named one of the top places to work in Atlanta for the second year in a row. The honor is “a testament to the supportive and enthusiastic environment that we foster,” says ACR Executive Vice President Mark Andrejeski…
FDA to Review Abuse Deterrent Oxycodone Capsule & More
The FDA will discuss a New Drug Application for Remoxy ER during an upcoming advisory committee meeting and recently approved tildrakizumab-asmn to treat adults with plaque psoriasis…
Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
A recent systematic review found no clear evidence that rheumatoid arthritis patients treated with cyclophosphamide have better lung function than those treated with mycophenolate mofetil. The researchers caution that physicians should expect treatment with cyclophosphamide may only result in a modest improvement in the preservation of forced vital capacity…
AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
(Reuters)—AbbVie Inc. on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc. that would fend off U.S. competition of their biosimilar version to blockbuster drug, adalimumab (Humira), until 2023. This is the second deal AbbVie has signed over the past year as it tries to safeguard patents on Humira,…
The ACR Updates Biosimilar Position Statement
In March, the ACR released a white paper designed primarily to help rheumatologists and rheumatology health professionals gain an understanding of biosimilars.1 This research-based education piece examines the scientific, economic and prescribing issues related to the use of biosimilars. Now, the ACR has released an update to its official position statement on the use of…
Arkansas PBM Bill: A Step in the Right Direction
During a three-day special legislative session in March, Arkansas Governor Asa Hutchinson (R) signed into law the first bill in the U.S. intended to address a lack of transparency among pharmacy benefit managers (PBMs) and their role in the high cost of prescription drugs.1 The bill, H.B. 1010: Arkansas Pharmacy Benefits Manager Licensure Act, will…
- « Previous Page
- 1
- …
- 347
- 348
- 349
- 350
- 351
- …
- 816
- Next Page »